ClinicalTrials.gg
CompletedNCT02584660MERCURY PEUpdated Jun 1, 2018Results posted

A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department

A Phase 4 interventional study of Rivaroxaban and Standard-of-care in Pulmonary Embolism, sponsored by Janssen Scientific Affairs, LLC. Completed at 50 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-06-01.

Sponsored by Janssen Scientific Affairs, LLC (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
114
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing rivaroxaban in Pulmonary Embolism — 4 open to participants now, 6 under way, 2 of them phase 3. Rivaroxaban · Pulmonary Embolism.

Enrollment
13th of 20
114 · median 241
Started
2015
with 1 other
Phase 4
6 of 20
1 open now
Registered
9th of 20
by date

Among the 20 studies testing rivaroxaban in Pulmonary Embolism, this one is the 13th largest by enrollment, is one of 2 that started in 2015, is one of 6 in phase 4, and was the 9th registered.

Pulmonary Embolism

832 studies on the registry are indexed under Pulmonary Embolism; 171 are open to participants now.

Browse Pulmonary Embolism studies →

Open to participants now

4 of the 20 studies testing rivaroxaban in Pulmonary Embolism are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About rivaroxaban

Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 129 Pulmonary Embolism studies recruiting now, 109 (84%) set no upper age limit and 5 (4%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing rivaroxaban in Pulmonary Embolism, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate that low risk Pulmonary Embolism (PE) participants who are discharged from the Emergency Department (ED) to the home environment and treated with rivaroxaban as outpatients have fewer total days in the hospital for bleeding and/or venous thromboembolism (VTE) events through Day 30 compared to participants who are treated with initial hospitalization and standard-of-care.

Read the detailed description

This is a randomized (study medication is assigned by chance), open-label (all people know the identity of the intervention), parallel-group, multicenter (study conducted at multiple sites) study to evaluate that low risk PE participants who are discharged from the ED and treated with rivaroxaban compared to participants who are treated with initial hospitalization and standard-of-care. The study consists of a Screening and Randomization Period, followed by a 90-day open-label treatment period, and an end of study/early withdrawal (EOS) visit. The duration of study participation for each participant is approximately 3 months. The participants will be randomized in a 1:1 ratio to one of two treatments. Safety will be monitored during the study.

03

Conditions studied

  • Pulmonary Embolism

Browse trials for

Keywords

  • Rivaroxaban
  • JNJ39039039
  • Pulmonary embolism
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have confirmed acute symptomatic Pulmonary Embolism (PE) with or without symptomatic deep vein thrombosis (DVT)
  • A PE participant diagnosed in the Emergency Department (ED) who is deemed to be at low risk of clinical deterioration as determined by the Hestia criteria
  • Have no to and be able to complete randomized treatment and all study assessments
  • Have a of at least 6 months
  • Must be willing and able to adhere to the prohibitions and restrictions specified in this protocol

Exclusion criteria

Exclusion Criteria:

  • Having received any Combined P-gp (P-glycoprotein) and strong (Cytochrome P450) inhibitors (such as but not limited to ketoconazole, telithromycin or protease inhibitors) use within 4 days before randomization, or planned use during the study. Itraconazole use within 7 days before randomization or planned use during the study
  • Having received any Combined P-gp and strong CYP3A4 inducers (such as but not limited to rifampin/rifampicin, rifabutin, rifapentine, phenytoin, phenobarbital, carbamazepine, or St. John's Wort) use within 2 weeks before randomization or planned use during the study
  • Who Has to the use of any anticoagulant therapy (example, bleeding diathesis, history of gastrointestinal bleeding within 1 year or coagulopathy documented at Screening)
  • Who Has known allergies, , or intolerance to rivaroxaban or its
  • Woman who is pregnant, or breast-feeding, or planning to become pregnant
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
114 participants (actual)

Study arms

  • Experimental
    Rivaroxaban

    Participants will receive Rivaroxaban 15 milligram (mg) orally twice daily with food for the first 21 days followed by 20 mg orally once daily with food, for approximately 69 days for a total treatment duration of 90 days.

    Drug: Rivaroxaban

  • Experimental
    local Standard-of-care

    Participants will receive local Standard-of-care as per local protocol and defined by the medical team caring for the participant.

    Drug: Standard-of-care

Interventions

  • Participants will receive Rivaroxaban 15 milligram (mg) twice daily up to Days 21 by orally and Rivaroxaban 20 mg once daily up to Days 90 by orally.

  • DrugStandard-of-care

    Standard-of-care as per local protocol and defined by the medical team caring for the participant.

06

What researchers measure

Primary outcomes

  1. Mean Duration of Hospitalization

    Mean number of days of initial inpatient hospitalization (beginning from randomization to discharge from the hospital) plus any subsequent hospitalization(s) related to bleeding and/or venous thromboembolism (VTE) events up to 30 days were calculated.

    Time frame: Up to Day 30

Secondary outcomes

  1. Percentage of Participants With Reoccurrence of Symptomatic Venous Thromboembolism Event (VTE) (Composite of Recurrent PE, New or Recurrent DVT) or VTE-related Death

    Reoccurrence of symptomatic, objectively confirmed VTE, defined as recurrent pulmonary embolism (PE) or new or recurrent deep vein thrombosis (DVT) (including symptomatic upper extremity DVT) or VTE related death were analyzed.

    Time frame: Up to 7, 14, 30, and 90 Days

  2. Percentage of Participants With Number of Unplanned Hospital Visits or Physician Office for VTE Symptoms and/or Bleeding

    Percentage of participants of unplanned hospitalization for VTE symptoms or bleeding-related hospital or physician visits were analyzed.

    Time frame: Up to 7, 14, 30 and 90 Days

  3. Mean Combined Duration of Initial and Subsequent Emergency Department (ED) Hospitalization for Any Reason

    Mean combined duration of Initial and subsequent ED Stay and hospitalization for any reason within 30 and 90 days from randomization was analyzed.

    Time frame: Up to 30 and 90 Days

  4. Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS)

    ACTS is defined as a validated measure for assessing treatment satisfaction. The ACTS comprised of 2 subscales: Burdens (13 items: Item 1 to 13 \[how much of limitation from taking part in vigorous physical activities, limitation from usual activities, bothered by bruising, bothered to avoid other medicines, limitation to diet, daily hassle, occasional hassle, difficult to follow treatment, time-consuming, worrying, frustrating, burden, negative impact on life respectively) and Benefits (4 items: Items 14 to 17 for evaluating confidence, reassurance, satisfaction, positive impact respectively) as a result of anti-clot treatment. The treatment experience scores ranged from 'Not at all' to 'Extremely' on a 5-point Likert scale (psychometric rating); higher scores indicate greater satisfaction with treatment.

    Time frame: Day 90

  5. Percentage of Participants Satisfied Using Site-of-Care Satisfaction Questionnaire

    The Satisfaction to Site-of-Care Questionnaire (standard-of-care versus early discharge on rivaroxaban therapy) was administered after 7 days on anticoagulant therapy. Satisfaction to Site-of-Care (hospitalization versus home care) rates the participant's level of satisfaction to care and location with care received as well as preference to location of care provided. Participants rated the 3 items of this scale of 1=Very satisfied; 2=Quite satisfied; 3=Neither; 4=Quite dissatisfied; and 5=Very dissatisfied for satisfaction questions and for the 1 preference question responses included 1=In the hospital; 2=In the community; and 3=No preference. Higher score indicates more level of satisfaction.

    Time frame: Day 7

07

Results

Posted Apr 20, 2018

Participant flow

Participant flow — Overall Study
MilestoneRivaroxabanStandard-of-care
Started5163
Treated4963
Completed4455
Not completed78
Withdrew: Adverse event40
Withdrew: Lost to follow-up34
Withdrew: Protocol violation01
Withdrew: Withdrawal by subject02
Withdrew: Other01

Outcome measures

PrimaryMean Duration of Hospitalization

Mean number of days of initial inpatient hospitalization (beginning from randomization to discharge from the hospital) plus any subsequent hospitalization(s) related to bleeding and/or venous thromboembolism (VTE) events up to 30 days were calculated.

Time frame:
Up to Day 30
Reported as:
Mean · Days
Mean Duration of Hospitalization
DaysRivaroxabanStandard-of-care
Mean Duration of Hospitalization0.191 ± 0.68621.393 ± 1.9642
Statistical analysis
  • Rivaroxaban vs Standard-of-care · t-test · p = <.0001 · Mean difference: -1.202 · 95% CI -1.730 to -0.674
SecondaryPercentage of Participants With Reoccurrence of Symptomatic Venous Thromboembolism Event (VTE) (Composite of Recurrent PE, New or Recurrent DVT) or VTE-related Death

Reoccurrence of symptomatic, objectively confirmed VTE, defined as recurrent pulmonary embolism (PE) or new or recurrent deep vein thrombosis (DVT) (including symptomatic upper extremity DVT) or VTE related death were analyzed.

Time frame:
Up to 7, 14, 30, and 90 Days
Reported as:
Number · Percentage of participants
Percentage of Participants With Reoccurrence of Symptomatic Venous Thromboembolism Event (VTE) (Composite of Recurrent PE, New or Recurrent DVT) or VTE-related Death
Percentage of participantsRivaroxabanStandard-of-care
Up to 7 Days00
Up to 14 Days00
Up to 30 Days00
Up to 90 Days00
SecondaryPercentage of Participants With Number of Unplanned Hospital Visits or Physician Office for VTE Symptoms and/or Bleeding

Percentage of participants of unplanned hospitalization for VTE symptoms or bleeding-related hospital or physician visits were analyzed.

Time frame:
Up to 7, 14, 30 and 90 Days
Reported as:
Number · Percentage of Participants
Percentage of Participants With Number of Unplanned Hospital Visits or Physician Office for VTE Symptoms and/or Bleeding
Percentage of ParticipantsRivaroxabanStandard-of-care
Up to 7 Days00
Up to 14 Days20
Up to 30 Days3.91.6
Up to 90 Days3.96.3
SecondaryMean Combined Duration of Initial and Subsequent Emergency Department (ED) Hospitalization for Any Reason

Mean combined duration of Initial and subsequent ED Stay and hospitalization for any reason within 30 and 90 days from randomization was analyzed.

Time frame:
Up to 30 and 90 Days
Reported as:
Mean · Days
Mean Combined Duration of Initial and Subsequent Emergency Department (ED) Hospitalization for Any Reason
DaysRivaroxabanStandard-of-care
Within 30 Days0.679 ± 2.08941.513 ± 1.9952
Within 90 Days0.764 ± 2.18291.812 ± 2.714
SecondaryTreatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS)

ACTS is defined as a validated measure for assessing treatment satisfaction. The ACTS comprised of 2 subscales: Burdens (13 items: Item 1 to 13 \[how much of limitation from taking part in vigorous physical activities, limitation from usual activities, bothered by bruising, bothered to avoid other medicines, limitation to diet, daily hassle, occasional hassle, difficult to follow treatment, time-consuming, worrying, frustrating, burden, negative impact on life respectively) and Benefits (4 items: Items 14 to 17 for evaluating confidence, reassurance, satisfaction, positive impact respectively) as a result of anti-clot treatment. The treatment experience scores ranged from 'Not at all' to 'Extremely' on a 5-point Likert scale (psychometric rating); higher scores indicate greater satisfaction with treatment.

Time frame:
Day 90
Reported as:
Number · Percentage of participants
Treatment Satisfaction Assessment in Participants by Anti-clot Treatment Scale (ACTS)
Percentage of participantsRivaroxabanStandard-of-care
Item 1: Not at all51.161.8
Item 1: A little4021.8
Item 1: Moderately6.710.9
Item 1: Quite a bit2.21.8
Item 1: Extremely03.6
Item 2: Not at all77.870.9
Item 2: A little13.320
Item 2: Moderately6.77.3
Item 2: Quite a bit2.20
Item 2: Extremely01.8
Item 3: Not at all71.165.5
Item 3: A little22.221.8
Item 3: Moderately2.25.5
Item 3: Quite a bit4.45.5
Item 3: Extremely01.8
Item 4: Not at all6052.7
Item 4: A little33.320
Item 4: Moderately4.49.1
Item 4: Quite a bit2.210.9
Item 4: Extremely07.3
Item 5: Not at all8060
Item 5: A little17.816.4
Item 5: Moderately016.4
Item 5: Quite a bit2.27.3
Item 5: Extremely00
Item 6: Not at all75.656.4
Item 6: A little2025.5
Item 6: Moderately2.25.5
Item 6: Quite a bit2.212.7
Item 6: Extremely00
Item 7: Not at all73.345.5
Item 7: A little22.230.9
Item 7: Moderately4.420
Item 7: Quite a bit01.8
Item 7: Extremely01.8
Item 8: Not at all82.278.2
Item 8: A little15.612.7
Item 8: Moderately07.3
Item 8: Quite a bit2.21.8
Item 8: Extremely00
Item 9: Not at all84.474.5
Item 9: A little15.621.8
Item 9: Moderately01.8
Item 9: Quite a bit01.8
Item 9: Extremely00
Item 10: Not at all48.943.6
Item 10: A little28.916.4
Item 10: Moderately8.918.2
Item 10: Quite a bit11.110.9
Item 10: Extremely2.210.9
Item 11: Not at all77.860
Item 11: A little17.816.4
Item 11: Moderately4.47.3
Item 11: Quite a bit09.1
Item 11: Extremely07.3
Item 12: Not at all84.464.8
Item 12: A little15.618.5
Item 12: Moderately09.3
Item 12: Quite a bit03.7
Item 12: Extremely03.7
Item 13: Not at all64.454.5
Item 13: A little28.918.2
Item 13: Moderately4.414.5
Item 13: Quite a bit2.27.3
Item 13: Extremely05.5
Item 14: Not at all4.45.5
Item 14: A little8.97.3
Item 14: Moderately2021.8
Item 14: Quite a bit26.738.2
Item 14: Extremely4027.3
Item 15: Not at all4.45.6
Item 15: A little8.95.6
Item 15: Moderately2024.1
Item 15: Quite a bit35.642.6
Item 15: Extremely31.122.2
Item 16: Not at all8.95.5
Item 16: A little2.29.1
Item 16: Moderately15.69.1
Item 16: Quite a bit33.345.5
Item 16: Extremely4030.9
Item 17: Not at all2.27.3
Item 17: A little13.37.3
Item 17: Moderately17.818.2
Item 17: Quite a bit28.943.6
Item 17: Extremely37.823.6
SecondaryPercentage of Participants Satisfied Using Site-of-Care Satisfaction Questionnaire

The Satisfaction to Site-of-Care Questionnaire (standard-of-care versus early discharge on rivaroxaban therapy) was administered after 7 days on anticoagulant therapy. Satisfaction to Site-of-Care (hospitalization versus home care) rates the participant's level of satisfaction to care and location with care received as well as preference to location of care provided. Participants rated the 3 items of this scale of 1=Very satisfied; 2=Quite satisfied; 3=Neither; 4=Quite dissatisfied; and 5=Very dissatisfied for satisfaction questions and for the 1 preference question responses included 1=In the hospital; 2=In the community; and 3=No preference. Higher score indicates more level of satisfaction.

Time frame:
Day 7
Reported as:
Number · Percentage of participants
Percentage of Participants Satisfied Using Site-of-Care Satisfaction Questionnaire
Percentage of participantsRivaroxabanStandard-of-care
Satisfaction level: Very Satisfied60.462.7
Satisfaction level: Quite Satisfied33.323.7
Satisfaction level: Neither4.26.8
Satisfaction level: Quite Dissatisfied2.15.1
Satisfaction level: Very Dissatisfied01.7
Location of care: Very Satisfied62.559.3
Location of care: Quite Satisfied33.330.5
Location of care: Neither4.26.8
Location of care: Quite Dissatisfied01.7
Location of care: Very Dissatisfied01.7
Preference of care: In the Hospital18.847.5
Preference of care: In the Community5040.7
Preference of care: No Preference31.311.9

Adverse events

Collected over Approximately 2.5 years. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rivaroxaban0/49 (0%)5/49 (10.2%)15/49 (30.6%)
Standard-of-care0/63 (0%)7/63 (11.1%)13/63 (20.6%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventRivaroxabanStandard-of-care
DyspnoeaRespiratory, thoracic and mediastinal disorders0/493/63
Atrial FibrillationCardiac disorders1/490/63
Chest PainGeneral disorders1/490/63
PainGeneral disorders1/490/63
Device Related InfectionInfections and infestations1/490/63
SepsisInfections and infestations1/490/63
ArthralgiaMusculoskeletal and connective tissue disorders1/490/63
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders1/490/63
Systemic Inflammatory Response SyndromeGeneral disorders0/491/63
Embolic PneumoniaInfections and infestations0/491/63
Most frequent other events
Showing 10 of 11
Most frequent other events
EventRivaroxabanStandard-of-care
Chest PainGeneral disorders5/493/63
DyspnoeaRespiratory, thoracic and mediastinal disorders1/495/63
Pain in ExtremityMusculoskeletal and connective tissue disorders3/490/63
MenorrhagiaReproductive system and breast disorders3/491/63
HeadacheNervous system disorders2/493/63
SinusitisInfections and infestations2/490/63
Back PainMusculoskeletal and connective tissue disorders2/491/63
Muscle SpasmsMusculoskeletal and connective tissue disorders2/490/63
EpistaxisRespiratory, thoracic and mediastinal disorders2/491/63
Non-Cardiac Chest PainGeneral disorders0/492/63

Baseline characteristics

Age, Continuous
Age, Continuous(years)RivaroxabanStandard-of-careTotal
Mean49.1 ± 13.2747.6 ± 17.2248.3 ± 15.53
Sex: Female, Male
Sex: Female, Male(Participants)RivaroxabanStandard-of-careTotal
Female273259
Male243155
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)RivaroxabanStandard-of-careTotal
Hispanic or Latino224
Not Hispanic or Latino4760107
Unknown or Not Reported213
Race (NIH/OMB)
Race (NIH/OMB)(Participants)RivaroxabanStandard-of-careTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American201434
White294877
More than one race000
Unknown or Not Reported112
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)RivaroxabanStandard-of-careTotal
Asian101
Black or African American201434
Hispanic or Latino224
Other112
White294877
Not Hispanic or Latino4760107
Region of Enrollment
Region of Enrollment(Participants)RivaroxabanStandard-of-careTotal
UNITED STATES5163114
08

Study locations

50 sites
  • Montgomery, Alabama, United States
  • Chandler, Arizona, United States
  • Phoenix, Arizona, United States
  • Tucson, Arizona, United States
  • Los Angeles, California, United States
  • Sacramento, California, United States
  • Sylmar, California, United States
  • New Haven, Connecticut, United States
  • Washington, District of Columbia, United States
  • Pensacola, Florida, United States
  • Tampa, Florida, United States
  • Davenport, Iowa, United States
  • Iowa City, Iowa, United States
  • Baltimore, Maryland, United States
  • Springfield, Massachusetts, United States
  • Detroit, Michigan, United States
  • Jackson, Michigan, United States
  • Lansing, Michigan, United States
  • Royal Oak, Michigan, United States
  • Saint Louis, Missouri, United States
  • Atlantic City, New Jersey, United States
  • Camden, New Jersey, United States
  • Brooklyn, New York, United States
  • Buffalo, New York, United States
  • New York, New York, United States
  • Stony Brook, New York, United States
  • Chapel Hill, North Carolina, United States
  • Charlotte, North Carolina, United States
  • Durham, North Carolina, United States
  • Winston-Salem, North Carolina, United States
  • Cincinnati, Ohio, United States
  • Cleveland, Ohio, United States
  • Toledo, Ohio, United States
  • Zanesville, Ohio, United States
  • Portland, Oregon, United States
  • Allentown, Pennsylvania, United States
  • Bethlehem, Pennsylvania, United States
  • Philadelphia, Pennsylvania, United States
  • Pittsburgh, Pennsylvania, United States
  • West Reading, Pennsylvania, United States
  • Charleston, South Carolina, United States
  • Dallas, Texas, United States
  • Fort Worth, Texas, United States
  • Houston, Texas, United States
  • Salt Lake City, Utah, United States
  • Charlottesville, Virginia, United States
  • Bellingham, Washington, United States
  • Everett, Washington, United States
  • Spokane, Washington, United States
  • Tacoma, Washington, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2015 to primary completion in Mar 2017, 17 months.

Results were first posted in Apr 2018, 1 year after primary completion.

Of 24 phase 4 interventional studies under Pulmonary Embolism, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 82. This study's 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2015
First posted
Oct 22, 2015
StartActual
Oct 15, 2015
Primary completionActual
Mar 22, 2017
CompletionActual
Mar 22, 2017
Results first posted
Apr 20, 2018
Last update
Jun 1, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02584660
Collaborators
Bayer
Responsible party
Sponsor
First posted
Oct 22, 2015
Start date
Oct 15, 2015
Primary completion
Mar 22, 2017
Completion
Mar 22, 2017
Results posted
Apr 20, 2018
Last update
Jun 1, 2018

Study contacts

Janssen Scientific Affairs, LLC Clinical Trial
study director · Janssen Scientific Affairs, LLC

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rivaroxaban

Start the discussion